...starts to submit a rolling BLA for panitumumab for colorectal cancerL. 6/29/01 - Partners with MDS Proteomics...

...for a Canadian biotech. The cancer company slots in behind a $56.9 million round for MDS Proteomics...

...earnings exclude a $30.1 million impairment charge associated with a write-off of its investment in MDS Proteomics...

...MDS subsidiary MDS Proteomics discontinued its drug discovery and development business to focus on providing services in...
...and development business to focus on providing services in biomarker identification, lead optimization and proteomics. MDS Proteomics...
...which will use them to develop assays for use in preclinical trials. MDS will pay MDS Proteomics...

...MDS subsidiary MDS Proteomics partnered with Eli Lilly Canada Inc. (Toronto, Ontario) to research the use of...

...CEPH will use MDS subsidiary MDS Proteomics Inc.’s differential analysis, chemiproteomics, PhosMap phosphorylation fingerprinting and protein interaction...

...CEPH will use technology from MDS Proteomics , a subsidiary of MDS (TSE:MDS; MDZ), to aid in...

...whole cell lysate of S. cerevisiae, and led to the identification of 383 phosphorylation sites. MDS Proteomics...

...go cold, companies end up having to bail out the investors. That's what happened to MDS Proteomics...
...MDZ, Toronto, Ontario). Last April, MDS ended up buying back the special warrants sold by MDS Proteomics...
...of March, a promise made while the window was still open. Investors were fortunate that MDS Proteomics...

...cDNA clones. MDS will use the clones for mapping disease pathways and determining protein function. MDS Proteomics...